GSK/Vir Announces Final Data of Monoclonal Antibody Sotrovimab Phase 3 COMET-ICH Study

At present, the new crown pneumonia epidemic abroad is still spreading rapidly

Recently, GlaxoSmithKline (GSK) and Vir Biotech announced the final confirmation results of the Phase 3 COMET-ICE study (COVID-19 Monoclonal Antibody Efficacy Trial-Early Care Intention), which shows: Compared with placebo , The monoclonal antibody sotrovimab (formerly known as VIR-7831, GSK4182136) intravenous infusion therapy can significantly reduce the risk of hospitalization or death in high-risk outpatients with mild to moderate COVID-19

In the COMET-ICE study, the primary efficacy analysis of all 1057 patients showed that the study reached the primary endpoint: by day 29, compared with placebo, sotrovimab significantly reduced the risk of hospitalization for more than 24 hours or death from all causes79 % (Adjusted relative risk reduction; p<0.

At the end of May this year, the US FDA granted sotrovimab emergency use authorization (EUA) for the treatment of mild to moderate COVID-19 adult and pediatric patients (12 years old and above, weighing at least 40 kg), specifically: direct SARS-CoV -2 Patients who test positive for the virus and are at high risk of developing severe COVID-19 (including hospitalization and death)

Note: The original text has been deleted